Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Larotrectinib - Bayer/Loxo Oncology

Next Previous
Drug Profile

Larotrectinib - Bayer/Loxo Oncology

Alternative Names: AR-470; ARRY-470; BAY 2757556; Larotrectinib sulfate - Bayer/Loxo Oncology; LOXO 101; VITRAKVI

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Bayer; Loxo Oncology; National Cancer Institute (USA)
  • Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules; Tumour-agnostic therapies
  • Mechanism of Action TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Solid tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Solid tumours
  • Phase II Histiocytosis; Non-Hodgkin's lymphoma
  • Phase I/II CNS cancer

Most Recent Events

  • 10 Dec 2024 Efficacy and adverse events data from a phase II NAVIGATE trial and phase I/II SCOUT trail in Breast cancer were presented at the 47th Annual San Antonio Breast Cancer Symposium (SABCS-2024)
  • 31 May 2024 Updated pooled efficacy and adverse events data from a phase I trial, phase I/II SCOUT trial and the phase II NAVIGATE in Solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology, 2024 (ASCO-2024)
  • 20 Oct 2023 Updated pooled efficacy and adverse events data from a phase I trial, phase I/II SCOUT trial and the phase II NAVIGATE in Solid tumors presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top